# GLP-1 receptor agonists and obesity-related cancer risk

Source: https://onco.cc/technologies/glp1-agonists-cancer-risk/  
OnCo record `glp1-agonists-cancer-risk` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GLP-1 agonists, the new weight-loss injections, lower weight by 15-20%. Early observational data suggest fewer obesity-related cancers in people who take them, but no trial has yet tested cancer as an outcome.

## Summary

Obesity is causally linked to at least 13 cancers (IARC 2016). Semaglutide and tirzepatide produce 15-22% weight loss in trials and reduce cardiovascular events (SELECT, NEJM 2023). Several large cohort and target-trial-emulation studies in people with type 2 diabetes report 10-40% lower incidence of obesity-associated cancers (notably endometrial, kidney, liver, pancreatic and colorectal) with GLP-1 receptor agonists compared with insulin or other glucose-lowering drugs, and a signal for lower cancer risk than bariatric surgery in one study; these are observational with short follow-up and prone to immortal-time and surveillance biases. Thyroid C-cell tumours in rodents led to a label warning, with no convincing human medullary thyroid cancer signal so far; pancreatitis and pancreatic cancer concerns have not been borne out. Because these drugs are now used by millions, a randomised trial with cancer incidence as a primary endpoint, or pre-specified cancer endpoints in ongoing outcome trials, is feasible and important.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-09-08
- Principle: Sustained weight loss lowers adiposity-driven insulin, oestrogen and inflammatory signalling; GLP-1 receptor agonists may also have direct anti-proliferative or immunomodulatory effects independent of weight.
- Strengths: First scalable pharmacological route to reversing the obesity-cancer risk; Consistent direction of observational signals; Cardiometabolic benefits already proven
- Limitations: No randomised cancer endpoint; Observational biases; Cost, access and lean-mass loss with rapid weight reduction

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
- IARC Handbook: body fatness and cancer (NEJM 2016): https://doi.org/10.1056/NEJMsr1606602
- SELECT (NEJM 2023): https://doi.org/10.1056/NEJMoa2307563

## Connected records

- ideas: [A trial of GLP-1 weight-loss drugs with cancer as the primary outcome](https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/), [GLP-1 drugs to reverse endometrial precancer in women with obesity](https://onco.cc/ideas/idea-prev-glp1-endometrial-hyperplasia/), [GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer](https://onco.cc/ideas/idea-nl-glp1-adjuvant-hr-breast/), [Link bariatric and GLP-1 registries to cancer registries in every country that has both](https://onco.cc/ideas/idea-nl-bariatric-cancer-registry-linkage/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Craniopharyngioma](https://onco.cc/cancers/craniopharyngioma/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Bariatric surgery and cancer incidence](https://onco.cc/technologies/bariatric-surgery-cancer-incidence/), [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Dietitian-led weight-loss programmes in HR-positive breast cancer](https://onco.cc/technologies/dietitian-led-weight-loss-breast/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- terms: [Body composition (lean mass, fat mass, visceral fat)](https://onco.cc/terms/body-composition/), [Energy balance](https://onco.cc/terms/energy-balance/), [Metabolic syndrome and insulin resistance](https://onco.cc/terms/metabolic-syndrome/), [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/)
- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes](https://onco.cc/key-papers/paper-lincoff-n-engl-j-med/)
- pathways: [Lipid synthesis, uptake & cholesterol](https://onco.cc/pathways/lipid-metabolism-cancer/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/), [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/glp1-agonists-cancer-risk.json